

Amendments to the Specification:

Please replace the Abstract on page 29 with the following Abstract:

A1
A process for treating ~~Alzheimer's~~ Alzheimer's disease, comprising the steps of administering to a human patient an antagonist of a neurotransmitter receptor which indirectly inhibits ~~phosphorylation~~ phosphorylation of microtubule-associated protein-2, and thereafter administering to ~~said the patient and an~~ an anticholinesterase agent. The antagonist of the neurotransmitter binds to a neurotransmitter receptor which phosphorylates ~~said the~~ the microtubule-associated protein-2 in limbic cells, the antagonist of the neurotransmitter binds to a neurotransmitter receptor which phosphorylates microtubule-associated protein-2 in neocortical cells, and the antagonist binds to ~~said the~~ the neurotransmitter receptor in ~~said the~~ the limbic cells at least 1.5 times as much as it binds to ~~said the~~ the neurotransmitter receptor in ~~said the~~ the neocortical cells.

Please replace paragraph 1, page 8 beginning with "Other candidate antagonists..." with the following paragraph:

A2
Other candidate antagonists which may be utilized in steps 10 et seq. include antipsychotic medicines that are chiefly designed to produce dopamine antagonism but which also exhibit muscarinic antagonism (i.e., clozapine, olanzepine, chlorpromazine, haloperidol).

Please replace the paragraph beginning at line 14, page 12 beginning with "In one embodiment ..." with the following paragraph:

A3
In one embodiment, the required dosage of antagonist ~~be~~ is administered at least once a day. In another embodiment, the required antagonist is administered two or more times per day.

Please replace the paragraph beginning at line 1, page 19 beginning with "Lewington, and ..." with the following paragraph:

04 Lewington, and S. Szeto (The Cochrane Library, Issue 1, 2001), "...produced no clear results. The results were compatible with tacrine producing improvement, no change or even harm for those with Alzheimer's disease." The authors stated that "For measure of overall clinical improvement, the intention-to-treat analyses failed to detect any difference between tacrine and placebo...Behavioral disturbance, as measured by the Alzheimer's Disease Assessment Scale-noncognitive, failed to detect any difference between tacrine and placebo....For cognition function, the effect of tacrine was not statistically significantly different from placebo for the Mini-Mental State Examination score:..."

Please replace the paragraph beginning at line 17, page 20 beginning with "By way of illustration ..." with the following paragraph:

05 By way of illustration, controller 60 can vary the amount and/or rate of delivery and/or time of delivery of either antagonist (maintained in reservoir 62) and/or anticholinesterase (maintained in reservoir 64) and, as appropriate, feed such materials via line 66 to the patient's brain 68 54 by means of pump 70. By trying various combinations of drugs and/or delivery times and/or concentrations, the ideal protocol can be determined.